NL-201
Immunotherapy drug candidate
NL-201 was an immunotherapy drug candidate that underwent a Phase 1 human clinical trial in cancer patients. It is a de novo protein that was first computationally designed at the Institute of Protein Design (IPD), University of Washington. In November 2022, Neoleukin Therapeutics announced it would discontinue the development of NL-201.
01History
The predecessor of NL-201, neoleukin-2/15, was first described and published on Nature magazine in January 2019. The citizen science distributed computing project Rosetta@home, based at the University of Washington, contributed with "forward folding" experiments that helped validate protein designs of neoleukin-2/15, from which NL-201 was further developed by Neoleukin Therapeutics, a biopharmaceutical company that originated at the IPD.
The Phase 1 human clinical trial began on May 5, 2021.
In January 2022, Neoleukin Therapeutics announced a collaboration with Merck for a combination clinical trial of Merck's Pembrolizumab and Neoleukin's NL-201.
In November 2022, Neoleukin Therapeutics announced it would discontinue the development of NL-201.
Sources and credits
This article is adapted from the Wikipedia article “NL-201”, written by its contributors and licensed under CC BY-SA 4.0. Fathomly has changed the layout, removed citation markers, navigation and maintenance notices, and adjusted punctuation. This adapted version is shared under the same license. For references, see the original article.
Fathomly is not affiliated with or endorsed by the Wikimedia Foundation. Spotted a problem? Tell us.